



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1459
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/776,037

02/09/2004

Paul G. Yock

13854.4004

1520

34313

7590

01/18/2007

ORRICK, HERRINGTON & SUTCLIFFE, LLP
IP PROSECUTION DEPARTMENT
4 PARK PLAZA
SUITE 1600
IRVINE, CA 92614-2558

EXAMINER

MARVICH, MARIA

ART UNIT

PAPER NUMBER

1633

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
--	-----------	---------------

3 MONTHS

01/18/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary

Application No.

10/776,037

Applicant(s)

YOCK ET AL.

Examiner

Maria B. Marvich, PhD

Art Unit

1633

— The MAILING DATE of this communication appears on the cover sheet with the correspondence address —
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 20 March 2006.
- 2a) ☒ This action is FINAL. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-104 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-104 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 09 February 2004 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date 3/20/06.

- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____.

DETAILED ACTION

This office action is in response to an amendment filed 3/20/06 and 5/8/06. Claims 1, 8, 15, 37, 44, 51, 56, 67, 78 and 90 have been amended. Claims 101-104 have been added. Claims 1-104 are pending in this application.

This application is a reissue of United States Patent Number 6,346,098.

Oath/Declaration

Claims 1-104 are rejected as being based upon a defective reissue oath under 35 U.S.C. 251. See 37 CFR 1.175. The nature of the defect is set forth below. **This is a new rejection**

Applicants have amended the oath to state "We believe the '098 Patent to be partly inoperative or invalid" based upon a broadening reissue application. However, the stated error in the oath does not reflect a broadening reissue. In fact, the stated error only pertains to dependent claims that were added and this alone does not constitute grounds for reissue.

Furthermore, the OATH/DECLARATION precedes the latest amendment. However, amendments have been made after filing of the oath.

In accordance with 37 CFR 1.175(b)(1), a supplemental reissue oath/declaration under 37 CFR 1.175(b)(1) must be received before this reissue application can be allowed.

As well,

It does not identify the mailing address of each inventor. A mailing address is an address at which an inventor customarily receives his or her mail and may be either a home or business address. The mailing address should include the ZIP Code designation. The mailing address may be provided in an application data sheet or a supplemental oath or declaration. See 37 CFR 1.63(c) and 37 CFR 1.76. Specifically, the mailing address of Peter Fitzgerald is missing.

Claim Rejections - 35 USC § 112, first paragraph

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-104 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter, which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. **This is a new rejection necessitated by applicants' amendment.**

The limitation that either the agent or a fluid delivery vehicle produces a disruption in the vessel has been added to the claims. Applicant has not indicated where support for this limitation is found. The examiner has been unable to find literal support in the originally filed specification for this limitation. The specification does not teach that either the agent or the fluid delivery vehicle is responsible for causing the disruption of the vessel. Rather, the specification teaches that the agent is "administered in combination with the application of stress to the vascular tissue associated with the vascular site of administration and it is the production of stress that results in disruption of the vascular vessel (see col 4, line 36-46). As well, this stress can be physical, chemical or a combination of the two. By physical is meant mechanical stress such as external forces i.e. electroporation, RF energy. By chemical stress is meant inflammatory agents or tissue disrupting agent. These teachings do not suggest or disclose that

the biological agent that is delivered to the vascular vessel is responsible for the disruption. While, the specification teaches that chemical agents can be used to disrupt the vessel, there is no teaching that the chemical agent is also the biological agent. Therefore, the limitation is impermissible NEW MATTER.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1-3, 7-11, 13-19, 21-23, 29-39, 43-47 and 49-100 are rejected under 35 U.S.C. 102(e) as being anticipated by Wolff et al (US 6,867,196; see entire document). **This rejection is maintained for reasons of record in the office action mailed 9/16/05 and restated below. However, the rejection has been slightly reworded based upon applicants' amendment. Claims 60, 71, 83 and 94 were indicated as rejected in the body of the rejection, but were inadvertently omitted from the heading of the rejection. These claims have been added to the heading of the claim rejection to correctly reflect the body of the rejection.**

Wolff et al teach methods of delivering nucleic acid to cardiac tissue using a catheter (forming a channel) into cardiac tissue from a vessel (vein or artery, see e.g. col 8, line 10-19), The instant specification defines interstitial space as the region or tissue beyond the wall of the

Art Unit: 1633

vascular site or beyond the intimal space (see e.g. bridging paragraph col 3-4). The method involves a retrograde approach with increased permeability of the vessels as recited in claims 1, 2, 8, 10, 13, 14, 21-23, 30 and 36-38 (see e.g. abstract, col 9, line 4-27 and col 11, line 1-65). Permeability of the vessel is increased by intravascular hydrostatic pressure by the fluid delivery vehicle as recited in claims 15-18, 44, 46, 49-53 (see e.g. col 11, line 1-55), this increased permeability results in channels to the heart and is equal to a disruption in the vessel such that agent is delivered to the interstitial space. Stress is placed proximal to the interstitial space and can be chemical (see e.g. col 11, line 34-54) as recited in claims 3, 29 and 39. As well, the stress can also be mechanical as it is generated by clamping (see e.g. col 11, line 1-21) as recited in claims 7, 9, 43, 45, 56-59, 61, 68, 78-82 and 84. A catheter is used that has an occlusion device downstream of the site of administration of the agent (see e.g. figure 3) as recited in claims 32, 34, 63, 65, 74, 76, 86, 88, 97 and 99. As demonstrated in figure 4 and figure 3, the catheter comprises an occlusion device that is upstream and downstream of the site of administration. The specification does not define venous (venous) branches. During prosecution, claims must be interpreted as broadly as their terms reasonably allow. Thus, as depicted in figure 4, the catheter would place an occlusion device such that at least one upstream branch of the vessel can be occluded as recited in claims 33, 64, 75, 87 and 98. This should necessarily result in disruption through increased permeability of the venous branches upstream of the vessel as recited in claims 31, 35, 62, 66, 73, 77, 85, 89, 96 and 100. Finally, Wolff et al teach that nucleic acids encoding cytokines can be delivered. Many cytokines are responsible for producing inflammatory responses. Thus it would be inherent that administration of cytokines would lead to production of inflammation in the vessels as recited in claims 11, 19, 47, 55, 60, 71, 83 and 94.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1, 4-6, 8, 12, 15, 20, 24, 28, 37, 40-42, 44, 48, 51, 56-59, 61-70, 71-82, 84-93 and 95-104 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wolff et al (US 6,867,196; see entire document) in view of Makower et al (US 2002/0179098; see entire document). **This is a new rejection necessitated by applicants' amendment.**

Applicants claim a method of locally administering an active agent comprising retroinfusing an agent into a vascular vessel under conditions sufficient for an agent or fluid delivery vehicle to produce a disruption which method further comprises administration of energy to the vessel. As well, the agent is delivered to a myocardial space and the agent can be cells or dye or imaging agents, the vessel can be a venous branch.

The teachings of Wolff et al are described above and are applied as before except;

Wolff et al do not teach that the method further comprises administration of energy to the vessel, the agent is delivered to a myocardial space and the agent can be cells or dye or imaging agents.

Makower et al teach a method of locally administering an active agent such as xenograft tissue (which inherently comprise cells, peptides, proteins and nucleic acids) signal emitting targets or radiological imaging material, imaging means or dyes (see e.g. paragraph 0012, 0097,

0109 and 0161) in which the agent is retroinfused into a vascular vessel such as a vein under conditions sufficient to disrupt the vein such that the agent enters interstitial space such as the myocardial space as recited in claims 6, 12, 20, 24, 42 and 48 (see e.g. paragraph 0097). The method further comprises administration of energy to the vein such as heat as recited in claim 5, 28, 41, 56-59, 61-70, 71-82, 84-93 and 95-104 (see e.g. paragraph 0114, claims 75 and 76). Heat is used to keep the non-stented passageways open and to prevent scarring as well as a depot means carrying the cells as recited in claim 4 and 40 (see e.g. paragraph 0169).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to locally deliver to the myocardial beds an agent by retroinfusion such that a disruption results in the vascular vessel to the interstitial space as taught by Wolffe et al in which the disruption is produced in the myocardial interstitial space and to then apply energy such as heat in the method as taught by Makower et al because Wolffe et al teach that it is within the ordinary skill of the art to retroinfuse agents into a vascular vessel such that a passageway to the interstitial space is created and because Makower et al teach that it is within the ordinary skill of the art to deliver agents to the myocardial space following retroinfusion and to apply energy such as heat during the method. One would have been motivated to do so in order to receive the expected benefit of delivery to the myocardial space to treat coronary artery disease and for revascularization in which a passageway to the myocardial interstitial space has been generated using xenograft tissue and has been treated with heat to decrease incidence of scarring and incidence of closure. Based upon the teachings of the cited references, the high skill of one of ordinary skill in the art, and absent evidence to the contrary, there would have been a reasonable expectation of success to result in the claimed invention.

Claims 1 and 25-27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wolff et al (US 6,867,196; see entire document). **This rejection is maintained for reasons of record in the office action mailed 9/16/05 and restated below.**

Applicants claim a method of locally administering an active agent to a host by retroinfusing said agent into the vessel under pressure of at least 50mm Hg, 60 mm Hg and 1000 mm Hg.

The teachings of Wolff et al are described above and are applied as before except;

Wolff et al do not teach that the pressure used during retroinfusion is at least 50mm Hg, 60mm Hg and 1000mm Hg.

It would have been obvious to someone of skill in the art to utilize pressure of at least 50mm Hg, 60 mm Hg and 1000 mm Hg in the method of Wolff et al given that the identification of these pressures would be required to optimize the hydrostatic pressure to permeabilize or disrupt the vessels for deliverance of the agents. A person of skill in the art would have been motivated to optimize these conditions to best utilize the methods of Wolff et al for deliverance of agents to interstitial spaces. The MPEP teaches "Generally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." see also Peterson, 315 F.3d at 1330, 65 USPQ2d at 1382 ("The normal desire of scientists or artisans to improve upon what is already generally known provides the motivation to determine where in a disclosed set of percentage

ranges is the optimum combination of percentages”). Given the teachings of the cited art and the level of skill of the ordinary skilled artisan at the time of the applicant’s invention, it must be considered that said ordinary skilled artisan would have had a reasonable expectation of success in practicing the claimed invention.

Response to Argument

Applicants traverse the claim rejections under 35 U.S.C. 102 and 103 on pages 11-13 of the amendment filed 3/20/06. Applicants argue that i.e. col 6, line 52 to col 7, line 11, Wolff et al do not teach conditions under which the vessel walls are disrupted nor use of energy in the administrative method.

Applicants’ arguments filed 3/20/06 have been fully considered but they are not persuasive. Applicants specifically rely on teachings by Wolffe et al that injection of DNA was performed such that no major histological abnormalities were detected as if this should indicate that no disruptions in the vasculature were formed. However, Wolffe et al further teach that in a preferred embodiment, the intravascular pressure of the blood vessel is increased by increasing osmotic pressure with in the blood vessel with hypertonic solutions or use of chemicals. In col 11, line 39-41 Wolffe et al teach, “biologically active molecules that affect permeability interact with a specific receptor or enzyme or protein with the vascular cell to change the vessel’s permeability”. Specifically, Wolffe et al teach administration of plasmid DNA under conditions such that the agent or fluid delivery vehicle results in disruption of the vasculature. In example 3, the DNA is administered under increased venous pressure 1-350 mmHg followed by administration of hypertonic solution. Taken as a whole, the teachings of Wolffe et al are

directed toward administration of agents under pressure or chemical conditions such that permeability or disruption of the vasculature occurs resulting in delivery of the agent to the interstitial space.

Secondly, applicants' claims are now drawn to delivery of the agents under conditions in which the agent of fluid delivery vehicles cause disruption of the vascular vessel in which energy is also applied. As stated above, Makower et al teach that it is known in the art to administer energy during retrograde delivery of agents to the vascular. By combining the teachings of Wolffe et al and Makower et al, one of skill in the art would have used energy as taught by Makower et al in the methods of Wolffe et al to improve delivery to myocardial tissue and interstitial space as detailed above.

Conclusion

No Claims allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event,


however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maria B. Marvich, PhD whose telephone number is (571)-272-0774. The examiner can normally be reached on M-F (7:00-4:00).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Woitach, PhD can be reached on (571)-272-0739. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Maria B Marvich, PhD
Examiner
Art Unit 1633



SCOTT D. PRIEBE, PH.D
PRIMARY EXAMINER